Todd N. Eagar

Todd N. Eagar

Auto-generated profile, based on publicly available information

Todd N. Eagar

Department of Pathology and Genomic Medicine Houston Methodist Hospital Houston Texas USA

Research Focus & Metrics

Academic Career Length

25Years (2002-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
1 December 2020 in Journal of Clinical Investigation
Verified
Journal Article
Closed access
PDF file
ESEric Salazar
Eric Salazar
Suresh V. KuchipudiSuresh V. Kuchipudi
Suresh V. Kuchipudi
PCPaul A. Christensen
Paul A. Christensen
TETodd Eagar
Todd Eagar
XYXin Yi
Xin Yi
JMJames M. Musser
James M. Musser
The newly emerged severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) highlights the urgent need for assays that detect protective levels of neutralizing antibodies. We studied the relationship among anti-spike ectodomain (anti-ECD), anti–receptor-binding domain (anti-RBD) IgG titers, and SARS-CoV-2 virus neutralization (VN) titers generated by 2 in vitro assays using convalescent plasma samples from 68 patients with COVID-19. We report a strong positive correlation between both plasma anti-RBD and anti-ECD IgG titers and in vitro VN titers. The probability of a VN titer of ≥160, the FDA-recommended level for convalescent plasma used for COVID-19 treatment, was ≥80% when anti-RBD or anti-ECD titers were ≥1:1350. Of all donors, 37% lacked VN titers of ≥160. Dyspnea, hospitalization, and disease severity were significantly associated with higher VN titer. Frequent donation of convalescent plasma did not significantly decrease VN or IgG titers. Analysis of 2814 asymptomatic adults found 73 individuals with anti-ECD IgG titers of ≥1:50 and strong positive correlation with anti-RBD and VN titers. Fourteen of these individuals had VN titers of ≥1:160, and all of them had anti-RBD titers of ≥1:1350. We conclude that anti-RBD or anti-ECD IgG titers can serve as a surrogate for VN titers to identify suitable plasma donors. Plasma anti-RBD or anti-ECD titers of ≥1:1350 may provide critical information about protection against COVID-19 disease.

2 August 2010 in European Journal of Immunology
Verified
Journal Article
Open access
PDF file
CHChristopher T. Harp
Christopher T. Harp
SISara Ireland
Sara Ireland
LDLaurie S. Davis
Laurie S. Davis
GRGina Remington
Gina Remington
BCBonnie Cassidy
Bonnie Cassidy
NMNancy L. Monson
Nancy L. Monson
Recent evidence suggests that B‐ and T‐cell interactions may be paramount in relapsing‐remitting MS (RRMS) disease pathogenesis. We hypothesized that memory B‐cell pools from RRMS patients may specifically harbor a subset of potent neuro‐APC that support neuro‐Ag reactive T‐cell proliferation and cytokine secretion. To test this hypothesis, we compared CD80 and HLA‐DR expression, IL‐10 and lymphotoxin‐α secretion, neuro‐Ag binding capacity, and neuro‐Ag presentation by memory B cells from RRMS patients to naïve B cells from RRMS patients and to memory and naïve B cells from healthy donors (HD). We identified memory B cells from some RRMS patients that elicited CD4+ T‐cell proliferation and IFN‐γ secretion in response to myelin basic protein and myelin oligodendrocyte glycoprotein. Notwithstanding the fact that the phenotypic parameters that promote efficient Ag presentation were observed to be similar between RRMS and HD memory B cells, a corresponding capability to elicit CD4+ T‐cell proliferation in response to myelin basic protein and myelin oligodendrocyte glycoprotein was not observed in HD memory B cells. Our results demonstrate for the first time that the memory B‐cell pool in RRMS harbors neuro‐Ag specific B cells that can activate T cells.

30 March 2021 in Proceedings of the National Academy of Sciences
Verified
Journal Article
Open access
PDF file
NMNavid Manouchehri
Navid Manouchehri
RHRehana Z. Hussain
Rehana Z. Hussain
PCPetra D. Cravens
Petra D. Cravens
EEEkaterina Esaulova
Ekaterina Esaulova
MAMaxim N. Artyomov
Maxim N. Artyomov
OSOlaf Stuve
Olaf Stuve
Significance: The bone marrow-derived CD11c+CD88+CD317+myeloid cells within the central nervous system are associated with clinical experimental autoimmune encephalomyelitis. Transcriptional analyses identifyITGAX-(CD11c),C5AR1-(CD88), andBST2-(CD317) expressing cells as a distinct myeloid subset in human cerebrospinal fluid. The disease-propagating effects of these cells in experimental autoimmune encephalomyelitis can be effectively antagonized using anti-CD317 monoclonal antibody therapy.

26 January 2022 in Clinical Transplantation
Verified
Journal Article
Open access
PDF file
HHHoward J Huang
Howard J Huang
SYStephanie G. Yi
Stephanie G. Yi
CMConstance M. Mobley
Constance M. Mobley
ASAshish Saharia
Ashish Saharia
ABArvind Bhimaraj
Arvind Bhimaraj
MGMark Ghobrial
Mark Ghobrial
Response to two doses of a nucleoside‐modified messenger ribonucleic acid (mRNA) vaccine was evaluated in a large solid‐organ transplant program. mRNA COVID‐19 vaccine was administered to transplant candidates and recipients who met study inclusion criteria. Qualitative anti‐SARS‐CoV‐2 Spike Total Immunoglobulin (Ig) and IgG‐specific assays, and a semi‐quantitative test for anti‐SARS‐CoV‐2 Spike protein IgG were measured in 241 (17.2%) transplant candidates and 1163 (82.8%) transplant recipients; 55.2% of whom were non‐Hispanic White and 44.8% identified as another race. Transplant recipients were a median (IQR) of 3.2 (1.1, 6.8) years from transplantation. Response differed by transplant status: 96.0% versus 43.2% by the anti‐SARS‐CoV‐2 Total Ig (candidates vs. recipients, respectively), 93.5% versus 11.6% by the anti‐SARS‐CoV‐2 IgG assay, and 91.9% versus 30.1% by anti‐spike titers after two doses of vaccine. Multivariable analysis revealed candidates had higher likelihood of response versus recipients (odds ratio [OR], 14.6; 95 %CI 2.19, 98.11; P = .02). A slightly lower response was demonstrated in older patients (OR .96; 95 %CI .94, .99; P = .002), patients taking antimetabolites (OR, .21; 95% CI .08, .51; P = .001). Vaccination prior to transplantation should be encouraged.

23 February 2023 in Human Immunology
Verified
Journal Article
Closed access
GRGarrett R. Roll
Garrett R. Roll
RBRobert A. Bray
Robert A. Bray
MCMatthew Cooper
Matthew Cooper
TETodd N. Eagar
Todd N. Eagar
HGHoward M. Gebel
Howard M. Gebel
RRRaja Rajalingam
Raja Rajalingam

8 August 2018 in PLOS ONE
Verified
Journal Article
Open access
PDF file
MCMatthew Cummings
Matthew Cummings
AAAnitha Christy Sigamani Arumanayagam
Anitha Christy Sigamani Arumanayagam
PZPicheng Zhao
Picheng Zhao
SKSunil Kannanganat
Sunil Kannanganat
OSOlaf Stuve
Olaf Stuve
TETodd N Eagar
Todd N Eagar
Multiple Sclerosis (MS) is an inflammatory demyelinating disease of the central nervous system (CNS) where pathology is thought to be regulated by autoreactive T cells of the Th1 and Th17 phenotype. In this study we sought to understand the functions of Presenilin 1 (PSEN1) in regulating T cell effector responses in the experimental autoimmune encephalomyelitis (EAE) murine model of MS. PSEN1 is the catalytic subunit of γ-secretase a multimolecular protease that mediates intramembranous proteolysis. γ-secretase is known to regulate several pathways of immune importance. Here we examine the effects of disrupting PSEN1 functions on EAE and T effector differentiation using small molecule inhibitors of γ-secretase (GSI) and T cell-specific conditional knockout mice (PSEN1 cKO). Surprisingly, blocking PSEN1 function by GSI treatment or PSEN1 cKO had little effect on the development or course of MOG35-55-induced EAE. In vivo GSI administration reduced the number of myelin antigen-specific T cells and suppressed Th1 and Th17 differentiation following immunization. In vitro, GSI treatment inhibited Th1 differentiation in neutral but not IL-12 polarizing conditions. Th17 differentiation was also suppressed by the presence of GSI in all conditions and GSI-treated Th17 T cells failed to induce EAE following adoptive transfer. PSEN cKO T cells showed reduced Th1 and Th17 differentiation. We conclude that γ-secretase and PSEN1-dependent signals are involved in T effector responses in vivo and potently regulate T effector differentiation in vitro, however, they are dispensable for EAE.